Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
BioInvent International AB
Modality
monoclonal_antibody
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06784648CT.gov Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT05987332CT.gov IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | — | Active Not Recruiting | — | — | — |
NCT05576077CT.gov A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05341349CT.gov Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT05524935CT.gov Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | — | Recruiting | — | — | — |
NCT05308901CT.gov Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma | — | Active Not Recruiting | — | — | — |
NCT05282901CT.gov Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) | — | Active Not Recruiting | — | — | — |
NCT04855435CT.gov Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | — | Recruiting | — | — | — |
NCT03611868CT.gov A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02697630CT.gov Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT03070392CT.gov Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | — | Completed | — | — | — |
NCT02359851CT.gov Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | BioInvent International AB | P2/3 | BB · 68 |
| Ifa | Craig L Slingluff, Jr | P2 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Sargramostim | Thomas Jefferson University | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2/3 | BB |
| Darovasertib | IDEAYA Biosciences | P3 | BB |
| Gm-Csf | Ahmad Tarhini | P2 | BB |
| Thalidomide | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
+42 more in the Uveal Melanoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-uveal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →